Best Chance Products sells COVID-19 Real-Time PCR test kits, now available with swabs and VTM kits, antibody tests, hand sanitizer, gloves, masks, and an EPA-registered disinfectant that provides protection against germs and viruses, including the Coronavirus.
The COVID-19 Real Time PCR kits received Emergency Use Authorization from the United States Food and Drug Administration and has 100% clinical sensitivity and specificity.
With fast results and the capacity to produce approximately 200,000 tests each day, Best Chance Products is uniquely positioned to pave the way to an efficient testing strategy throughout multiple state governments, hospitals, and major healthcare companies in the United States and abroad.
For more information visit bestchanceproducts.com.
Best Chance Products is a distribution and sales company that provides a large supply chain of personal protective equipment, on both a wholesale and retail basis.
The company sells COVID-19 real time PCR testing kits made in South Korea, now available with swabs and VTM kits, antibody tests, hand sanitizer, gloves, masks, and EPA-registered disinfectants that provide protection against germs and viruses, including the Coronavirus.
As the exclusive distributor for BioCore, the global biomechanical engineering company at the forefront of FDA/EUA authorized COVID-19 tests, Best Chance Products distinguishes itself with quality and accuracy, aiming to provide efficient solutions for the needs of clients, while protecting the physical safety, health, and environment of individuals.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation